{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:33:32Z","timestamp":1707525212521},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,6]]},"DOI":"10.7759\/cureus.44799","type":"journal-article","created":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T04:28:55Z","timestamp":1694060935000},"source":"Crossref","is-referenced-by-count":0,"title":["Pembrolizumab-Induced Myasthenia Gravis and Peripheral Neuropathy: A Case Series"],"prefix":"10.7759","author":[{"given":"Sean M","family":"McCormack","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amar","family":"Hamad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Highlights of prescribing information Keytruda (pembrolizumab). (2021). https.\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125514s096lbl.pdf."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-015-0078-9","article-title":"Pembrolizumab","volume":"3","author":"Khoja L","year":"2015","unstructured":"Khoja L, Butler MO, Kang SP, Ebbinghaus S, Joshua AM. Pembrolizumab. J Immunother Cancer. 2015, 3:36. 10.1186\/s40425-015-0078-9","journal-title":"J Immunother Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome","volume":"8","author":"Alsaab HO","year":"2017","unstructured":"Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, Iyer AK. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017, 8:561. 10.3389\/fphar.2017.00561","journal-title":"Front Pharmacol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k793","article-title":"Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis","volume":"360","author":"Baxi S","year":"2018","unstructured":"Baxi S, Yang A, Gennarelli RL, Khan N, Wang Z, Boyce L, Korenstein D. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ. 2018, 360:k793. 10.1136\/bmj.k793","journal-title":"BMJ"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.e21519","article-title":"Incidence of immune-related adverse events with pembrolizumab in advanced melanoma and correlation with treatment response: a single institution review of irAEs","volume":"39","author":"Myrdal CN","year":"2021","unstructured":"Myrdal CN, Mehta P, Smith E, Briones K. Incidence of immune-related adverse events with pembrolizumab in advanced melanoma and correlation with treatment response: a single institution review of irAEs. J Clin Oncol. 2021, 39:e21519. 10.1200\/JCO.2021.39.15_suppl.e21519","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0263402","article-title":"Retrospective analysis of clinical trial safety data for pembrolizumab reveals the effect of co-occurring infections on immune-related adverse events","volume":"17","author":"Makunts T","year":"2022","unstructured":"Makunts T, Burkhart K, Abagyan R, Lee P. Retrospective analysis of clinical trial safety data for pembrolizumab reveals the effect of co-occurring infections on immune-related adverse events. PLoS One. 2022, 17:e0263402. 10.1371\/journal.pone.0263402","journal-title":"PLoS One"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.14740\/jmc4008","article-title":"Pembrolizumab-induced myasthenia gravis and myositis: literature review on neurological toxicities of programmed death protein 1 inhibitors","volume":"13","author":"Schwab A","year":"2022","unstructured":"Schwab A, Assaad M, Hamadi R, et al.. Pembrolizumab-induced myasthenia gravis and myositis: literature review on neurological toxicities of programmed death protein 1 inhibitors. J Med Cases. 2022, 13:530-5. 10.14740\/jmc4008","journal-title":"J Med Cases"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2017.06.002","article-title":"A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab","volume":"44","author":"Fessas P","year":"2017","unstructured":"Fessas P, Lee H, Ikemizu S, Janowitz T. A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab. Semin Oncol. 2017, 44:136-40. 10.1053\/j.seminoncol.2017.06.002","journal-title":"Semin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/cei\/uxac108","article-title":"Clinical features, diagnosis, and management of pembrolizumab-induced myasthenia gravis","volume":"211","author":"Zhao S","year":"2023","unstructured":"Zhao S, Zhou Y, Sun W, Li Z, Wang C. Clinical features, diagnosis, and management of pembrolizumab-induced myasthenia gravis. Clin Exp Immunol. 2023, 211:85-92. 10.1093\/cei\/uxac108","journal-title":"Clin Exp Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.05.041","article-title":"Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors","volume":"82","author":"Makarious D","year":"2017","unstructured":"Makarious D, Horwood K, Coward JI. Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors. Eur J Cancer. 2017, 82:128-36. 10.1016\/j.ejca.2017.05.041","journal-title":"Eur J Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow MA","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018, 378:158-68. 10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer JR","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018, 36:1714-68. 10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0372-x","article-title":"Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology","volume":"16","author":"Schrezenmeier E","year":"2020","unstructured":"Schrezenmeier E, D\u00f6rner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020, 16:155-66. 10.1038\/s41584-020-0372-x","journal-title":"Nat Rev Rheumatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4081\/reumatismo.2015.849","article-title":"Myasthenia gravis due to hydroxychloroquine","volume":"67","author":"Varan O","year":"2015","unstructured":"Varan O, Kucuk H, Tufan A. Myasthenia gravis due to hydroxychloroquine. Reumatismo. 2015, 67:849. 10.4081\/reumatismo.2015.849","journal-title":"Reumatismo"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.7722","article-title":"Association of immune checkpoint inhibitors with neurologic adverse events: a systematic review and meta-analysis","volume":"5","author":"Farooq MZ","year":"2022","unstructured":"Farooq MZ, Aqeel SB, Lingamaneni P, et al.. Association of immune checkpoint inhibitors with neurologic adverse events: a systematic review and meta-analysis. JAMA Netw Open. 2022, 5:e227722. 10.1001\/jamanetworkopen.2022.7722","journal-title":"JAMA Netw Open"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21165774","article-title":"Immune-driven pathogenesis of neurotoxicity after exposure of cancer patients to immune checkpoint inhibitors","volume":"21","author":"Vilari\u00f1o N","year":"2020","unstructured":"Vilari\u00f1o N, Bruna J, Kalofonou F, Anastopoulou GG, Argyriou AA. Immune-driven pathogenesis of neurotoxicity after exposure of cancer patients to immune checkpoint inhibitors. Int J Mol Sci. 2020, 21:10.3390\/ijms21165774","journal-title":"Int J Mol Sci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.29245\/2572.942X\/2016\/4.1040","article-title":"Central nervous system toxicities of anti-cancer immune checkpoint blockade","volume":"1","author":"Blackmon JT","year":"2016","unstructured":"Blackmon JT, Viator T, Conry RM. Central nervous system toxicities of anti-cancer immune checkpoint blockade. J Neurol Neuromedicine. 2016, 1:39-45. 10.29245\/2572.942X\/2016\/4.1040","journal-title":"J Neurol Neuromedicine"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.08.007","article-title":"Pembrolizumab-induced encephalopathy: a review of neurological toxicities with immune checkpoint inhibitors","volume":"12","author":"Feng S","year":"2017","unstructured":"Feng S, Coward J, McCaffrey E, Coucher J, Kalokerinos P, O'Byrne K. Pembrolizumab-induced encephalopathy: a review of neurological toxicities with immune checkpoint inhibitors. J Thorac Oncol. 2017, 12:1626-35. 10.1016\/j.jtho.2017.08.007","journal-title":"J Thorac Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinph.2019.03.035","article-title":"Electrophysiological findings in immune checkpoint inhibitor-related peripheral neuropathy","volume":"130","author":"Chen X","year":"2019","unstructured":"Chen X, Haggiagi A, Tzatha E, DeAngelis LM, Santomasso B. Electrophysiological findings in immune checkpoint inhibitor-related peripheral neuropathy. Clin Neurophysiol. 2019, 130:1440-5. 10.1016\/j.clinph.2019.03.035","journal-title":"Clin Neurophysiol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21093054","article-title":"Immune checkpoint inhibitor-related myositis: from biology to bedside","volume":"21","author":"Solimando AG","year":"2020","unstructured":"Solimando AG, Crudele L, Leone P, et al.. Immune checkpoint inhibitor-related myositis: from biology to bedside. Int J Mol Sci. 2020, 21:10.3390\/ijms21093054","journal-title":"Int J Mol Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/185984-pembrolizumab-induced-myasthenia-gravis-and-peripheral-neuropathy-a-case-series","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:06:17Z","timestamp":1707509177000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/185984-pembrolizumab-induced-myasthenia-gravis-and-peripheral-neuropathy-a-case-series"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,6]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.44799","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,6]]}}}